NO850536L - Fremgangsmaate for analysering av en proeve med hensyn paa interferon epsilon. - Google Patents

Fremgangsmaate for analysering av en proeve med hensyn paa interferon epsilon.

Info

Publication number: NO850536L
Authority: NO; Norway
Prior art keywords: interferon; cells; epsilon; stated; sample
Prior art date: 1984-07-06

Application number

NO850536A

Other languages

English (en)

Norwegian (no)

Inventor

Roy H L Pang

Original Assignee

Damon Biotech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-07-06

Filing date

1985-02-12

Publication date

1986-01-07

1985-02-12 Application filed by Damon Biotech Inc filed Critical Damon Biotech Inc

1986-01-07 Publication of NO850536L publication Critical patent/NO850536L/no

Links

102100026688 Interferon epsilon Human genes 0.000 title claims description 45
101710147309 Interferon epsilon Proteins 0.000 title claims description 45
238000000034 method Methods 0.000 title claims description 16
238000005070 sampling Methods 0.000 title 1
210000004027 cell Anatomy 0.000 claims description 33
102000014150 Interferons Human genes 0.000 claims description 32
108010050904 Interferons Proteins 0.000 claims description 32
210000002919 epithelial cell Anatomy 0.000 claims description 26
241000700605 Viruses Species 0.000 claims description 24
210000002510 keratinocyte Anatomy 0.000 claims description 24
210000002950 fibroblast Anatomy 0.000 claims description 21
229940079322 interferon Drugs 0.000 claims description 18
239000000523 sample Substances 0.000 claims description 16
102000003996 Interferon-beta Human genes 0.000 claims description 11
108090000467 Interferon-beta Proteins 0.000 claims description 11
102000006992 Interferon-alpha Human genes 0.000 claims description 10
108010047761 Interferon-alpha Proteins 0.000 claims description 10
102000008070 Interferon-gamma Human genes 0.000 claims description 7
108010074328 Interferon-gamma Proteins 0.000 claims description 7
241000711975 Vesicular stomatitis virus Species 0.000 claims description 7
208000015181 infectious disease Diseases 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
229940044627 gamma-interferon Drugs 0.000 claims description 3
238000011534 incubation Methods 0.000 claims description 3
230000003472 neutralizing effect Effects 0.000 claims description 3
238000007865 diluting Methods 0.000 claims description 2
230000035899 viability Effects 0.000 claims 3
239000012470 diluted sample Substances 0.000 claims 1
230000000694 effects Effects 0.000 description 19
229940047124 interferons Drugs 0.000 description 14
230000000840 anti-viral effect Effects 0.000 description 13
238000002360 preparation method Methods 0.000 description 11
238000003556 assay Methods 0.000 description 8
238000004113 cell culture Methods 0.000 description 8
238000006386 neutralization reaction Methods 0.000 description 7
241000711404 Avian avulavirus 1 Species 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
229960001388 interferon-beta Drugs 0.000 description 4
239000000126 substance Substances 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000710188 Encephalomyocarditis virus Species 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000009982 effect on human Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
229960003130 interferon gamma Drugs 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000007758 minimum essential medium Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101000836540 Homo sapiens Aldo-keto reductase family 1 member B1 Proteins 0.000 description 1
101000809450 Homo sapiens Amphiregulin Proteins 0.000 description 1
101000928259 Homo sapiens NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 description 1
101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000711408 Murine respirovirus Species 0.000 description 1
102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000011324 bead Substances 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
102000046818 human AR Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000013365 molecular weight analysis method Methods 0.000 description 1
108091006934 mouse interferon-epsilon Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000005373 porous glass Substances 0.000 description 1
244000144977 poultry Species 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000012521 purified sample Substances 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/811—Interferon
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Pathology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO850536A 1984-07-06 1985-02-12 Fremgangsmaate for analysering av en proeve med hensyn paa interferon epsilon. NO850536L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/628,612 US4675282A (en)	1984-07-06	1984-07-06	Assay for interferon epsilon

Publications (1)

Publication Number	Publication Date
NO850536L true NO850536L (no)	1986-01-07

Family

ID=24519613

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO850536A NO850536L (no)	1984-07-06	1985-02-12	Fremgangsmaate for analysering av en proeve med hensyn paa interferon epsilon.

Country Status (14)

Country	Link
US (1)	US4675282A (da)
JP (1)	JPS6125060A (da)
AU (1)	AU3857085A (da)
BE (1)	BE902663A (da)
CA (1)	CA1244345A (da)
CH (1)	CH666285A5 (da)
DE (1)	DE3515803A1 (da)
DK (1)	DK99185A (da)
FR (1)	FR2567269A1 (da)
GB (1)	GB2161270A (da)
IT (1)	IT1183809B (da)
NL (1)	NL8501564A (da)
NO (1)	NO850536L (da)
SE (1)	SE8500620L (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1299099C (en) *	1986-03-06	1992-04-21	Paul Richard Wood	In vitro assay for detecting cell-mediated immune responses
EP1037995A1 (en)	1997-12-08	2000-09-27	Genentech, Inc.	Human interferon-epsilon: a type 1 interferon
ZA9811070B (en)	1997-12-08	2000-07-03	Genentech Inc	Type I interferons.
BRPI0507169A (pt)	2004-02-02	2007-06-26	Ambrx Inc	polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
MX344166B (es)	2008-02-08	2016-12-07	Ambrx Inc	Leptina-polipeptidos modificados y sus usos.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1443425A (en) *	1972-10-25	1976-07-21	Searle & Co	Interferon assay
US3910824A (en) *	1973-10-18	1975-10-07	Searle & Co	Interferon assay
US4241174A (en) *	1978-11-24	1980-12-23	Hoffmann-La Roche Inc.	Interferon assay
JPS56135420A (en) *	1980-03-26	1981-10-22	Fumiaki Taguchi	Suppressive substance of virus and its preparation
DK319883A (da) *	1982-07-12	1984-01-13	Damon Biotech Inc	Interferonpraeparat
IL66733A (en) *	1982-09-07	1986-03-31	Yeda Res & Dev	Assay for ifn and kit therefor

1984
- 1984-07-06 US US06/628,612 patent/US4675282A/en not_active Expired - Fee Related
1985
- 1985-02-07 CA CA000473754A patent/CA1244345A/en not_active Expired
- 1985-02-08 AU AU38570/85A patent/AU3857085A/en not_active Abandoned
- 1985-02-12 NO NO850536A patent/NO850536L/no unknown
- 1985-02-12 SE SE8500620A patent/SE8500620L/xx not_active Application Discontinuation
- 1985-03-04 DK DK99185A patent/DK99185A/da not_active Application Discontinuation
- 1985-03-25 JP JP6051285A patent/JPS6125060A/ja active Pending
- 1985-04-30 IT IT67398/85A patent/IT1183809B/it active
- 1985-05-02 DE DE19853515803 patent/DE3515803A1/de not_active Ceased
- 1985-05-31 NL NL8501564A patent/NL8501564A/nl not_active Application Discontinuation
- 1985-06-12 FR FR8508919A patent/FR2567269A1/fr active Pending
- 1985-06-14 BE BE0/215192A patent/BE902663A/fr not_active IP Right Cessation
- 1985-07-05 CH CH2898/85A patent/CH666285A5/de not_active IP Right Cessation
- 1985-07-05 GB GB08517164A patent/GB2161270A/en not_active Withdrawn

Also Published As

Publication number	Publication date
CA1244345A (en)	1988-11-08
CH666285A5 (de)	1988-07-15
JPS6125060A (ja)	1986-02-03
SE8500620L (sv)	1986-01-07
BE902663A (fr)	1985-09-30
DK99185D0 (da)	1985-03-04
DK99185A (da)	1986-01-07
SE8500620D0 (sv)	1985-02-12
US4675282A (en)	1987-06-23
NL8501564A (nl)	1986-02-03
AU3857085A (en)	1986-01-09
GB2161270A (en)	1986-01-08
FR2567269A1 (fr)	1986-01-10
GB8517164D0 (en)	1985-08-14
DE3515803A1 (de)	1986-01-16
IT8567398A0 (it)	1985-04-30
IT8567398A1 (it)	1986-10-30
IT1183809B (it)	1987-10-22

Publication	Publication Date	Title
Hatmal et al.	2022	Comprehensive literature review of monkeypox
Chang et al.	1978	Physical, morphological, and biochemical alterations in the membrane of AKR mouse cells after interferon treatment.
Hartley et al.	1965	Complement fixation and tissue culture assays for mouse leukemia viruses.
Evans	1976	Cytological methods for detecting chemical mutagens
Finter	1964	Quantitative haemadsorption, a new assay technique: I. Assay of interferon
Yeh et al.	1982	Automated, quantitative cytopathic effect reduction assay for interferon
Bowser et al.	1985	Isolation of channel catfish virus from channel catfish, lctalurus punctatus (Rafinesque), broodstock.
Jeney et al.	1993	An in vitro technique for surveying immunostimulants in fish
Chen et al.	2018	Establishing a safe, rapid, convenient and low-cost antiviral assay of interferon bioactivity based on recombinant VSV expressing GFP
NO850536L (no)	1986-01-07	Fremgangsmaate for analysering av en proeve med hensyn paa interferon epsilon.
Melville et al.	2004	Bluetongue virus does not persist in naturally infected cattle
Yanni et al.	2021	Virological, molecular and immuno-biochemical studies of lumpy skin disease in naturally infected cattle
Gates et al.	2009	Quantitative measurement of varicella-zoster virus infection by semiautomated flow cytometry
McClain et al.	1958	Plaque morphology and pathogenicity of vesicular exanthema virus
Smith et al.	1977	A rapid quantitative assay for lymphotoxin
Kurta	1979	Bat rabies in Michigan
Risley et al.	1990	An improved method for cytogenetic analysis of meiotic aneuploidy in rodent and frog spermatocytes
Rossi et al.	1980	Factors affecting the assay of bovine type I interferon on bovine embryonic lung cells
Minkin et al.	1985	Multiwell chamber chemotaxis assays: improved experimental design and data analysis
Schüler et al.	2021	A testudinid herpesvirus 1 (TeHV1)-associated disease outbreak in a group of Horsfield’s tortoises (Testudo horsfieldii)
Chen et al.	2002	Failure of extracts from Malassezia pachydermatis to stimulate canine keratinocyte proliferation in vitro
Fuller et al.	1979	Cell surface‐associated ribonuclease activities
Weller et al.	1965	Biological characteristics of rubella virus as assayed in a human amnion culture system
Gamal Elden et al.	2021	Virological, Molecular and Immuno-Biochemical Studies of Lumpy Skin Disease in Naturally Infected Cattle
EP0817836B1 (de)	2004-04-07	Zellinie und verfahren zur vermehrung von tollwutviren und deren quantitativen nachweis